Skip to main content

Client News

AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement

24th January 2024

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

24th January 2024

BioLizard announces Swiss subsidiary and service offering for AI-powered digital transformation of life sciences at Biopôle in Lausanne

23rd January 2024

Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months

22nd January 2024

Kizoo leads financing round in Reservoir Neuroscience to restore health to the aging brain

18th January 2024

Affluent Medical: Pre-submission dossier for the 510(k) of medical device Kalios filed with FDA for review

15th January 2024

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

11th January 2024

Mainz Biomed Provides Year-End Corporate Review 2023

9th January 2024

AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS® for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients

9th January 2024

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

4th January 2024